BRIEF-Esperion Partners With Neopharm To Commercialize Nexletol® (Bempedoic Acid) And Nexlizet® (Bempedoic Acid And Ezetimibe) In Israel

Reuters2024-12-12

Dec 12 (Reuters) - Esperion Therapeutics ESPR.O:

ESPERION PARTNERS WITH NEOPHARM TO COMMERCIALIZE NEXLETOL® (BEMPEDOIC ACID) AND NEXLIZET® (BEMPEDOIC ACID AND EZETIMIBE) IN ISRAEL
ESPERION THERAPEUTICS INC: UNDER TERMS OF AGREEMENT, ESPERION WILL RECEIVE AN UPFRONT AND NEAR-TERM MILESTONE PAYMENTS
ESPERION THERAPEUTICS INC: UNDER TERMS OF AGREEMENT, ESPERION WILL BE ELIGIBLE TO RECEIVE TIERED ROYALTIES ON SALES OF NEXLETOL/NEXLIZET IN ISRAEL

Source text: ID:nGNX52X8ZR

Further company coverage: ESPR.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490838817?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-12 21:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490838817","market":"us","top_or_hot":-1,"title":"BRIEF-Esperion Partners With Neopharm To Commercialize Nexletol® (Bempedoic Acid) And Nexlizet® (Bempedoic Acid And Ezetimibe) In Israel","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Esperion Partners With Neopharm To Commercialize Nexletol® (Bempedoic Acid) And Nexlizet® (Bempedoic Acid And Ezetimibe) In Israel</title></head><body><p><span>Dec 12 (Reuters)</span><span> - </span>Esperion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>ESPR.O</span>:</p><ul><li><p>ESPERION PARTNERS WITH NEOPHARM TO COMMERCIALIZE NEXLETOL® (BEMPEDOIC ACID) AND NEXLIZET® (BEMPEDOIC ACID AND EZETIMIBE) IN ISRAEL</p></li><li><p>ESPERION THERAPEUTICS INC: UNDER TERMS OF AGREEMENT, ESPERION WILL RECEIVE AN UPFRONT AND NEAR-TERM MILESTONE PAYMENTS</p></li><li><p>ESPERION THERAPEUTICS INC: UNDER TERMS OF AGREEMENT, ESPERION WILL BE ELIGIBLE TO RECEIVE TIERED ROYALTIES ON SALES OF NEXLETOL/NEXLIZET IN ISRAEL</p></li></ul><p>Source text: <span>ID:nGNX52X8ZR</span></p><p>Further company coverage: <span>ESPR.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Esperion Partners With Neopharm To Commercialize Nexletol® (Bempedoic Acid) And Nexlizet® (Bempedoic Acid And Ezetimibe) In Israel</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Esperion Partners With Neopharm To Commercialize Nexletol® (Bempedoic Acid) And Nexlizet® (Bempedoic Acid And Ezetimibe) In Israel\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-12 21:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nFWN3ND05J:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Esperion Partners With Neopharm To Commercialize Nexletol® (Bempedoic Acid) And Nexlizet® (Bempedoic Acid And Ezetimibe) In IsraelDec 12 (Reuters) - Esperion Therapeutics ESPR.O:ESPERION ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nFWN3ND05J:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nFWN3ND05J:1","article_id":"2490838817","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490838817","pubTimestamp":1734008619,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Esperion Partners With Neopharm To Commercialize Nexletol (Bempedoic Acid) And Nexlizet (Bempedoic Acid And Ezetimibe) In IsraelDec 12 (Reuters) - Esperion Therapeutics ESPR.O:ESPERION PARTNERS ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ESPR":"Esperion Therapeutics Inc."},"translate_title":"简介-Esperion与Neopharm合作在以色列商业化Nexletol®（Bempedoic Acid）和Nexlizet®（Bempedoic Acid和依折麦布）","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ESPR":0.9},"content_text":"BRIEF-Esperion Partners With Neopharm To Commercialize Nexletol® (Bempedoic Acid) And Nexlizet® (Bempedoic Acid And Ezetimibe) In IsraelDec 12 (Reuters) - Esperion Therapeutics ESPR.O:ESPERION PARTNERS WITH NEOPHARM TO COMMERCIALIZE NEXLETOL® (BEMPEDOIC ACID) AND NEXLIZET® (BEMPEDOIC ACID AND EZETIMIBE) IN ISRAELESPERION THERAPEUTICS INC: UNDER TERMS OF AGREEMENT, ESPERION WILL RECEIVE AN UPFRONT AND NEAR-TERM MILESTONE PAYMENTSESPERION THERAPEUTICS INC: UNDER TERMS OF AGREEMENT, ESPERION WILL BE ELIGIBLE TO RECEIVE TIERED ROYALTIES ON SALES OF NEXLETOL/NEXLIZET IN ISRAELSource text: ID:nGNX52X8ZRFurther company coverage: ESPR.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490838817"}